Afatinib in Patients with Advanced HER2 Mutation-Positive (M plus ) NSCLC Previously Treated with Chemotherapy

被引：0
|
作者：
Zhou, Caicun [1 ]
Fan, Yun [2 ]
Wang, Huijuan [3 ]
Liam, Chong Kin [4 ]
Hu, Chengjie [5 ]
Cseh, Agnieszka [6 ]
机构：
[1] Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
[2] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Internal Med, Zhengzhou, Henan, Peoples R China
[4] Univ Malaya Med Ctr, Dept Med, Kuala Lumpur, Malaysia
[5] Boehringer Ingelheim China Investment Co Ltd, Beijing, Peoples R China
[6] Boehringer Ingelheim Rcv GmbH & Co KG, Dept Med Affairs, Vienna, Austria
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
NSCLC; afatinib; HER2; phase II;
D O I：
10.1016/j.jtho.2016.11.1506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-013
引用
收藏
页码：S1077 / S1077
页数：1
相关论文
共 50 条
  • [1] Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC
    Thongprasert, S.
    Geater, S. L.
    Clement, D.
    Abdelaziz, A.
    Reyes-Igama, J.
    Jovanovic, D.
    Alexandru, A.
    Schenker, M.
    Sriuranpong, V.
    Serwatowski, P.
    Suresh, S.
    Cseh, A.
    Gaafar, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 146 - 146
  • [2] Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC
    Santos, Edgardo
    Kaplan, Barry
    Kirshner, Eli
    Croft, Elisabeth
    Sequist, Lecia
    Burke, Lea
    Munley, Jiefen
    Oxnard, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1237 - S1237
  • [3] Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
    Lamb, Yvette N.
    TARGETED ONCOLOGY, 2021, 16 (05) : 687 - 695
  • [4] Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
    Yvette N. Lamb
    Targeted Oncology, 2021, 16 : 687 - 695
  • [5] Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommonmutations: Overview of clinical data
    Maerten, A.
    Yamamoto, N.
    Yu, C-J.
    Ou, S-H. I.
    Zhou, C.
    Wu, Y-L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S95 - S95
  • [6] Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program
    Peters, S.
    Curioni-Fontecedro, A.
    Nechushtan, H.
    Shih, J-Y.
    Liao, W-Y.
    Gautschi, O.
    Spataro, V.
    Unk, M.
    Yang, J. C-H.
    Lorence, R.
    Carriere, P.
    Cseh, A.
    Chang, G-C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Afatinib in Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Uncommon Mutations: Overview of Clinical Data
    Arrieta, O.
    De Marchi, P.
    Yamamoto, N.
    Yu, C.
    Ou, S. I.
    Zhou, C.
    Paskevicius, M.
    Maerten, A.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S165 - S165
  • [8] Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
    Yvette N. Lamb
    Targeted Oncology, 2021, 16 : 869 - 869
  • [9] Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R.
    Halmos, B.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1045 - S1045
  • [10] Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R. A.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2018, 29
12345